GlassScriptPhysician profile
Lawrence W Kemp
NPI 1619916855
$23,683.52
in general payments reported to CMS, 2019-2025
58 companies · $2,172 in 2025
The $2,172 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,438 · 2020: $2,759 · 2021: $4,193 · 2022: $3,871 · 2023: $3,595 · 2024: $3,655 · 2025: $2,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,319 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,318.99 |
| Education | $103.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $3,566.30 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Biogen, INC. | $1,684.93 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Ucb, INC. | $1,531.64 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| Abbvie INC. | $1,413.08 | 2020-2025 | |
| Lilly USA, LLC | $1,035.34 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Emd Serono, INC. | $999.74 | 2019-2025 | Mavenclad |
| Mallinckrodt Hospital Products INC. | $820.36 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $816.88 | 2019-2025 | |
| Genentech USA, INC. | $809.70 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Amneal Pharmaceuticals LLC | $791.92 | 2020-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Eisai INC. | $772.67 | 2019-2025 | |
| Amgen INC. | $719.58 | 2019-2025 | Uplizna |
| Acadia Pharmaceuticals INC | $715.42 | 2019-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $666.25 | 2019-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $568.31 | 2019-2025 | Vyepti |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Kemp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.